Matches in Wikidata for { <http://www.wikidata.org/entity/Q68163931> ?p ?o ?g. }
Showing items 1 to 47 of
47
with 100 items per page.
- Q68163931 description "article scientifique publié en 1990" @default.
- Q68163931 description "artikull shkencor i botuar më 01 janar 1990" @default.
- Q68163931 description "artículu científicu espublizáu en xineru de 1990" @default.
- Q68163931 description "im Januar 1990 veröffentlichter wissenschaftlicher Artikel" @default.
- Q68163931 description "scientific article published on 01 January 1990" @default.
- Q68163931 description "wetenschappelijk artikel" @default.
- Q68163931 description "наукова стаття, опублікована в січні 1990" @default.
- Q68163931 name "Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation" @default.
- Q68163931 name "Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation" @default.
- Q68163931 name "Sustained-release" @default.
- Q68163931 type Item @default.
- Q68163931 label "Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation" @default.
- Q68163931 label "Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation" @default.
- Q68163931 label "Sustained-release" @default.
- Q68163931 prefLabel "Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation" @default.
- Q68163931 prefLabel "Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation" @default.
- Q68163931 prefLabel "Sustained-release" @default.
- Q68163931 P1433 Q68163931-0CDA189F-907D-4526-8D63-06E3802031DD @default.
- Q68163931 P1476 Q68163931-414554E0-D9B0-47BB-8793-456E8E8A2674 @default.
- Q68163931 P2093 Q68163931-0B5BD0BF-E9CB-48EB-94CC-269CB514A84B @default.
- Q68163931 P2093 Q68163931-9E573192-A23B-401E-9ADA-DD7F97306757 @default.
- Q68163931 P2093 Q68163931-ACEB9159-9623-44B7-9FF9-44ADB9C434DD @default.
- Q68163931 P2093 Q68163931-C32DDEA2-AC73-42B1-A940-F5809DFFF093 @default.
- Q68163931 P304 Q68163931-A34C1879-45D8-4449-9D92-5EFD2682EBB9 @default.
- Q68163931 P31 Q68163931-B71886B1-1038-4995-A622-E3E23ACD75E3 @default.
- Q68163931 P356 Q68163931-AE37DB5D-4460-42E6-8A7D-3F5B41DDC7FD @default.
- Q68163931 P433 Q68163931-7B46BD96-978B-410D-996A-F6F7EDBC5498 @default.
- Q68163931 P478 Q68163931-06F4BA80-152B-486A-BB9C-8E2F28C2D37F @default.
- Q68163931 P577 Q68163931-BB91E5B7-837C-49B6-95A8-B76B7CE1BDCA @default.
- Q68163931 P698 Q68163931-1CFBFA59-5A0E-4057-9F29-4BDCD1C80D8A @default.
- Q68163931 P921 Q68163931-48AF6E95-85AA-41D3-AD6D-A361658A3BBD @default.
- Q68163931 P356 MDS.870050407 @default.
- Q68163931 P698 1979657 @default.
- Q68163931 P1433 Q1486418 @default.
- Q68163931 P1476 "Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation" @default.
- Q68163931 P2093 "Cedarbaum JM" @default.
- Q68163931 P2093 "Clark M" @default.
- Q68163931 P2093 "Green-Parsons A" @default.
- Q68163931 P2093 "Toy LH" @default.
- Q68163931 P304 "298-303" @default.
- Q68163931 P31 Q13442814 @default.
- Q68163931 P356 "10.1002/MDS.870050407" @default.
- Q68163931 P433 "4" @default.
- Q68163931 P478 "5" @default.
- Q68163931 P577 "1990-01-01T00:00:00Z" @default.
- Q68163931 P698 "1979657" @default.
- Q68163931 P921 Q11085 @default.